Cargando…
Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov
BACKGROUND: The $1.1 billion investment in comparative effectiveness research will reshape the evidence-base supporting decisions about treatment effectiveness, safety, and cost. Defining the current prevalence and characteristics of comparative effectiveness (CE) research will enable future assessm...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253780/ https://www.ncbi.nlm.nih.gov/pubmed/22253698 http://dx.doi.org/10.1371/journal.pone.0028820 |
_version_ | 1782220772692983808 |
---|---|
author | Bourgeois, Florence T. Murthy, Srinivas Mandl, Kenneth D. |
author_facet | Bourgeois, Florence T. Murthy, Srinivas Mandl, Kenneth D. |
author_sort | Bourgeois, Florence T. |
collection | PubMed |
description | BACKGROUND: The $1.1 billion investment in comparative effectiveness research will reshape the evidence-base supporting decisions about treatment effectiveness, safety, and cost. Defining the current prevalence and characteristics of comparative effectiveness (CE) research will enable future assessments of the impact of this program. METHODS: We conducted an observational study of clinical trials addressing priority research topics defined by the Institute of Medicine and conducted in the US between 2007 and 2010. Trials were identified in ClinicalTrials.gov. Main outcome measures were the prevalence of comparative effectiveness research, nature of comparators selected, funding sources, and impact of these factors on results. RESULTS: 231 (22.3%; 95% CI 19.8%–24.9%) studies were CE studies and 804 (77.7%; 95% CI, 75.1%–80.2%) were non-CE studies, with 379 (36.6%; 95% CI, 33.7%–39.6%) employing a placebo control and 425 (41.1%; 95% CI, 38.1%–44.1%) no control. The most common treatments examined in CE studies were drug interventions (37.2%), behavioral interventions (28.6%), and procedures (15.6%). Study findings were favorable for the experimental treatment in 34.8% of CE studies and greater than twice as many (78.6%) non-CE studies (P<0.001). CE studies were more likely to receive government funding (P = 0.003) and less likely to receive industry funding (P = 0.01), with 71.8% of CE studies primarily funded by a noncommercial source. The types of interventions studied differed based on funding source, with 95.4% of industry trials studying a drug or device. In addition, industry-funded CE studies were associated with the fewest pediatric subjects (P<0.001), the largest anticipated sample size (P<0.001), and the shortest study duration (P<0.001). CONCLUSIONS: In this sample of studies examining high priority areas for CE research, less than a quarter are CE studies and the majority is supported by government and nonprofits. The low prevalence of CE research exists across CE studies with a broad array of interventions and characteristics. |
format | Online Article Text |
id | pubmed-3253780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32537802012-01-17 Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov Bourgeois, Florence T. Murthy, Srinivas Mandl, Kenneth D. PLoS One Research Article BACKGROUND: The $1.1 billion investment in comparative effectiveness research will reshape the evidence-base supporting decisions about treatment effectiveness, safety, and cost. Defining the current prevalence and characteristics of comparative effectiveness (CE) research will enable future assessments of the impact of this program. METHODS: We conducted an observational study of clinical trials addressing priority research topics defined by the Institute of Medicine and conducted in the US between 2007 and 2010. Trials were identified in ClinicalTrials.gov. Main outcome measures were the prevalence of comparative effectiveness research, nature of comparators selected, funding sources, and impact of these factors on results. RESULTS: 231 (22.3%; 95% CI 19.8%–24.9%) studies were CE studies and 804 (77.7%; 95% CI, 75.1%–80.2%) were non-CE studies, with 379 (36.6%; 95% CI, 33.7%–39.6%) employing a placebo control and 425 (41.1%; 95% CI, 38.1%–44.1%) no control. The most common treatments examined in CE studies were drug interventions (37.2%), behavioral interventions (28.6%), and procedures (15.6%). Study findings were favorable for the experimental treatment in 34.8% of CE studies and greater than twice as many (78.6%) non-CE studies (P<0.001). CE studies were more likely to receive government funding (P = 0.003) and less likely to receive industry funding (P = 0.01), with 71.8% of CE studies primarily funded by a noncommercial source. The types of interventions studied differed based on funding source, with 95.4% of industry trials studying a drug or device. In addition, industry-funded CE studies were associated with the fewest pediatric subjects (P<0.001), the largest anticipated sample size (P<0.001), and the shortest study duration (P<0.001). CONCLUSIONS: In this sample of studies examining high priority areas for CE research, less than a quarter are CE studies and the majority is supported by government and nonprofits. The low prevalence of CE research exists across CE studies with a broad array of interventions and characteristics. Public Library of Science 2012-01-09 /pmc/articles/PMC3253780/ /pubmed/22253698 http://dx.doi.org/10.1371/journal.pone.0028820 Text en Bourgeois et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Bourgeois, Florence T. Murthy, Srinivas Mandl, Kenneth D. Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov |
title | Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov |
title_full | Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov |
title_fullStr | Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov |
title_full_unstemmed | Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov |
title_short | Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov |
title_sort | comparative effectiveness research: an empirical study of trials registered in clinicaltrials.gov |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253780/ https://www.ncbi.nlm.nih.gov/pubmed/22253698 http://dx.doi.org/10.1371/journal.pone.0028820 |
work_keys_str_mv | AT bourgeoisflorencet comparativeeffectivenessresearchanempiricalstudyoftrialsregisteredinclinicaltrialsgov AT murthysrinivas comparativeeffectivenessresearchanempiricalstudyoftrialsregisteredinclinicaltrialsgov AT mandlkennethd comparativeeffectivenessresearchanempiricalstudyoftrialsregisteredinclinicaltrialsgov |